A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Authors
Plummer, RLorigan, Paul C
Steven, N
Scott, L
Middleton, M
Wilson, R
Mulligan, E
Curtin, N
Wang, D
Dewji, R
Abbattista, A
Gallo, J
Calvert, H
Affiliation
Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. ruth.plummer@ncl.ac.ukIssue Date
2013-05
Metadata
Show full item recordAbstract
poly(ADP ribose) polymerase inhibition has been shown to potentiate the cytotoxicity of DNA damaging agents. A phase I study of rucaparib and temozolomide showed that full-dose temozolomide could be given during PARP inhibition. We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma.Citation
A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. 2013, 71 (5):1191-9 Cancer Chemother PharmacolJournal
Cancer Chemotherapy and PharmacologyDOI
10.1007/s00280-013-2113-1PubMed ID
23423489Type
ArticleLanguage
enISSN
1432-0843ae974a485f413a2113503eed53cd6c53
10.1007/s00280-013-2113-1
Scopus Count
Collections
Related articles
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
- Authors: Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, Milhem M
- Issue date: 2014 Oct
- Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
- Authors: Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E, Kalofonos Ch, Skarlos D, Karabelis A, Kosmidis P
- Issue date: 2002 Jan 15
- Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
- Authors: Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H
- Issue date: 2008 Dec 1
- Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
- Authors: García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR
- Issue date: 2006 Aug
- Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
- Authors: Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N, Middleton MR
- Issue date: 2003 Jul 1